Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy
- 31 December 2005
- journal article
- review article
- Published by Elsevier BV in The Breast
- Vol. 14 (6), 466-479
- https://doi.org/10.1016/j.breast.2005.08.026
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Postoperative Adjuvant Therapy With Tamoxifen, Tegafur Plus Uracil, or Both in Women With Node-Negative Breast Cancer: A Pooled Analysis of Six Randomized Controlled TrialsJournal of Clinical Oncology, 2005
- A surrogate marker to monitor angiogenesis at lastCancer Cell, 2005
- Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesisImplications for cellular surrogate marker analysis of antiangiogenesisCancer Cell, 2005
- A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose RegimensCancer Research, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Effect of p53 Status on Tumor Response to Antiangiogenic TherapyScience, 2002
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals Of Oncology, 2002
- Metronomic scheduling: the future of chemotherapy?The Lancet Oncology, 2001
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJCI Insight, 2000
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993